Biora Therapeutics (BIOR) Q2 2024 earnings summary

Executive summary

• Achieved successful Phase 1 clinical trial for BT-600 using the NaviCap platform, demonstrating targeted and precise colon drug delivery with a strong safety profile for ulcerative colitis treatment.

• Significant progress made with the BioJet platform, including active partnership discussions with large pharma companies and expectation to finalize at least one deal soon.

• Net income of $6.5 million for Q2 2024, reversing a net loss in Q2 2023, driven by non-cash gains on warrant and derivative liabilities.

• Revenue increased to $318,000 in Q2 2024, primarily from collaboration revenue.

• Secured up to $16 million in new funding from existing investors, reflecting confidence in clinical and platform progress.

Financial highlights

• Operating expenses for Q2 2024 were $16.1 million, up from $14.9 million in Q2 2023, mainly due to higher R&D costs.

• Core OpEx spend was $11.7 million, primarily allocated to R&D programs.

• Net income for Q2 2024 was $6.5 million, aided by $22.8 million in non-cash gains.

• Cash and equivalents at June 30, 2024, totaled $5.1 million, with a working capital deficit and accumulated deficit of $948.7 million.

• Revenue for Q2 2024 was $318,000, with all revenue from collaboration and licensing.

Outlook and guidance

• Anticipate initiating a Phase 1B clinical study with BT-600 in ulcerative colitis patients by late 2024.

• Remain on track to secure a pharma partnership for the BioJet platform in 2024.

• Manufacturing capacity for NaviCap devices is sufficient for upcoming trials, with plans for further automation to scale production.

• R&D investment expected to remain flat in 2024 as clinical trials continue.

• BT-600 Phase 1 data to be presented at the American College of Gastroenterology annual meeting in October 2024.